Theorem Clinical Research appoints vp of global regulatory affairs

Brian Bollwage is a food and drug law expert

Theorem Clinical Research, a US contract research organisation (CRO), has appointed Brian Bollwage to the position of vice president of global regulatory affairs.

Bollwage was previously director of global regulatory science at Bristol-Myers Squibb and executive director and regulatory counsel of global regulatory intelligence at i3 Research.

He is a food and drug law expert and a graduate of Rutgers Law School. He currently serves as an associate professor of food and drug law at Temple University in Philadelphia.

You may also like

Research & Development

Chiltern to purchase Theorem Clinical Research

To expand its global reach and scientific expertise
Research & Development

Theorem opens clinical supplies facility in Frankfurt, Germany

The expansion will offer both ambient and refrigerated storage space
Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Regulatory

Hansa Biopharma submits BLA to FDA for Imlifidase in desensitisation for kidney transplantation

Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
Research & Development

CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing

Collaboration formed to accelerate biopharmaceutical manufacturing, combining high-performing CHO-MK cells and GMP-manufactured culture media
Regulatory

New pharmaceutical legislation in Europe agreed

The agreement is the most significant overhaul of the regulatory framework in more than 20 years and represents a huge opportunity to reshape medicines regulation in the EU
Manufacturing

Why aseptic processing is critical for microsphere drug manufacturing

As microsphere-based drug delivery systems move from niche innovation to commercial reality, manufacturers face growing pressure to guarantee sterility without compromising product integrity. Aseptic processing has become essential to meeting both regulatory expectations and patient safety requirements
Subscribe now